Close

Moderna to come up with combined Covid and flu booster by 2023

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

The Ultimate Pain Relief Guide: Proven Tips to Manage Discomfort Naturally

Pain is something that we all go through somehow...

Medical Negligence in 2025: Pharma’s Role in Ensuring Patient Safety

In the ever-evolving world of healthcare, the role of...

When Pharma Meets the Underworld: How Legitimate Drug Supply Chains and Illicit Drug Markets Collide

In today's global landscape, the intersection between legitimate pharmaceutical...

US drugmaker Moderna is working on a combined Covid-19 and flu booster shot, which could be available in some countries by fall 2023 at the earliest, CEO Stephane Bancel has said.

In his speech at the Davos Agenda, a virtual event being held this week by the World Economic Forum, Bancel said this date was a “best case scenario”, but that he believed it was possible for some countries next year, CNN reported.

He explained it was a goal for the company to have a single annual booster shot available to avoid “compliance issues” where people are wary about getting multiple shots every winter.

Meanwhile, Bancel also said that the company will have data available on its Omicron-specific Covid-19 vaccine in March.

“It should be in the clinic in the coming weeks. And we’re hoping in the March timeframe, we should be able to have data to share with regulators to figure out the next step forward,” he was quoted as saying in a panel conversation at Davos.

“That’s always been a great partnership between public health experts, the regulators and vaccine makers to figure out what’s the best path,” he said.

Scientists at Pfizer are also using the mRNA technology that helped Covid-19 vaccines succeed in exploring ways to inoculate the masses from the flu.

According to Pfizer CEO Albert Bourla, its Omicron-specific vaccine will be ready by March, while AstraZeneca is also looking at a variant-specific jab.

 

Latest stories

Related stories

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

The Ultimate Pain Relief Guide: Proven Tips to Manage Discomfort Naturally

Pain is something that we all go through somehow...

Medical Negligence in 2025: Pharma’s Role in Ensuring Patient Safety

In the ever-evolving world of healthcare, the role of...

When Pharma Meets the Underworld: How Legitimate Drug Supply Chains and Illicit Drug Markets Collide

In today's global landscape, the intersection between legitimate pharmaceutical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back